Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Interchangeability with Heplisav; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a 70-year-old patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis and HAB (Twinrix) for prophylaxis. On 13-JAN-2025, the patient received the 1st dose of Twinrix. On 13-FEB-2025, the patient received the 2nd dose of Heplisav b. On 24-JUL-2025, the patient received the 3rd dose of Twinrix. On 13-FEB-2025, 31 days after receiving Twinrix, Heplisav b and Twinrix and an unknown time after receiving Twinrix, Heplisav b and Twinrix, the patient experienced interchange of vaccine products (Verbatim: Interchangeability with Heplisav). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 24-JUL-2025 Other HCP reported that they had a question about a schedule for the vaccine (Twinrix) that was done improperly. So, the initial vaccine for 2 people, a couple, they got their initial Twinrix vaccine in 13-Jan-2025. When they were supposed to received dose 2 of Twinrix, they were given Heplisav in error by a different pharmacist which led to interchange of vaccine products. And on the day of reporting, 6 months later, they were trying to get dose 3 of Twinrix. This case is linked with US2025095849 reported by same reporter.; Sender's Comments: US-GSK-US2025095849:same reporter, Different patient